JOURNAL OF NEUROTRAUMA, 2017 · DOI: 10.1089/neu.2016.4596 · Published: February 1, 2017
This study investigates HMGB1, a protein that promotes inflammation, in patients with spinal cord injuries (SCI). HMGB1 is found to be elevated in preclinical models. The research measures HMGB1 levels in the plasma of adults with acute (within 1 week post-SCI) or chronic (1+ year post-SCI) injuries, comparing them to uninjured individuals. The data suggests that HMGB1 could be an early and persistent signal causing inflammation in SCI patients.
HMGB1 is proposed as a therapeutic target in acute SCI, as anti-HMGB1 therapies have shown promise in pre-clinical studies.
HMGB1 can serve as a biomarker to assess the severity and prognosis of SCI, aiding in the development of personalized treatment strategies.
Targeting HMGB1 might help manage the chronic inflammation associated with SCI, potentially reducing secondary medical complications.